

NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, April 28, 2007 - 8:30 am – 4:15 pm EST
Room: CHURCHILL A

Chair: Frances Shepherd

-
- | | | |
|------------|--|-----------------|
| 8:30 a.m. | <u>WELCOME AND ANNOUNCEMENTS</u> | Dr. F. Shepherd |
| 8:35 a.m. | <u>SUB-COMMITTEE REPORTS</u> | |
| | Small Cell | Dr. P. Ellis |
| | Radiation | Dr. Y. Ung |
| | Mesothelioma and Thymoma | Dr. C. Lee |
| | Correlative Sciences | Dr. M-S Tsao |
| 9:15 a.m. | <u>NON-SMALL CELL LUNG CANCER</u> | |
| | <u>SURGICAL ADJUVANT AND NEOADJUVANT AND LOCALLY ADVANCED TRIALS</u> | |
| | BR.16 - Randomized placebo controlled trial of adjuvant selenium in completely resected stage I NSCLC (ECOG) | Dr. M. Johnston |
| | BR.19 - Randomized trial of adjuvant gefitinib versus placebo after complete resection of Stage IB, II IIIA NSCLC | Dr. G. Goss |
| | BR.23 - Phase II trial of etoposide/cisplatin/XRT followed by surgery and consolidation docetaxel for Pancoast tumours (SWOG 0220) | Dr. G. Perry |
| | BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-III A NSCLC | Dr. C. Butts |
| | BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-III A NSCLC
<i>Economic analysis</i> | Dr. N. Leighl |
| | CALGB 140503 A Phase III randomized trial of lobectomy versus sub-lobar resection for small (≤ 2 cm) peripheral NSCLC | Dr. G. Darling |
| 10:30 a.m. | COFFEE BREAK (~15 MIN) | |

continued . . .

- 10:45 a.m. **ADVANCED NSCLC**
- BR.24 - Randomized trial of paclitaxel and carboplatin +/- AZD 2171
in advanced Non-SCLC Dr. S. Laurie
- N0723 -A Phase III biomarker validation study of second-line
therapy in patients with advanced NSCLC randomized to
pemetrexed versus erlotinib Dr. G. Liu
- Proposal for erlotinib +/- talactoferrin in 2nd & 3rd Line treatment of NSCLC Dr. F. Shepherd
- 11:30 a.m. **SMALL CELL LUNG CANCER**
- BR.20 - Randomized Phase II trial of ZD 6474 versus placebo
in responding patients with SCLC. Final Report Dr. A. Arnold
- Proposals and decision re radiation trial for LD SCLC Dr. A. Bezjak
- Chemotherapy +/- low molecular weight heparin Dr. C. Butts
- Etoposide/platinum +/- pomalidomide in extensive SCLC Dr. F. Shepherd
- 12:00 p.m. **LUNCH (90 MIN.)**
- 1:30 p.m. **IND STUDIES**
- IND.171 - Phase I/II trial of paclitaxel/carboplatin + AZD 2171 Dr. S. Laurie
- IND.175 - Phase I/II trial of gemcitabine/cisplatin + AZD 2171 Dr. G. Goss
- IND.180 - A Phase I/II trial of oral AMG706 with concurrent
Etoposide/cisplatin/XRt in Stage III NSCLC Dr. M. Florescu
- IND.183 - Phase II trial of sunitinib in 2nd-line treatment of
malignant mesothelioma Dr. S. Laurie
- Report from the IND Committee Dr. G. Goss
- 2:30 p.m. **RADIOTHERAPY STUDIES**
- BR.25 - Hypofractionated radiotherapy for medically
inoperable NSCLC Dr. P. Cheung
- BRC.1 - PCI in Non-SCLC Dr. A. Sun
- RTOG - PCI in SCLC Dr. A. Sun
- 3:00 p.m. **COFFEE BREAK (~15 MIN)**
- 3:15 p.m. **ECONOMIC AND DATA-BASE ANALYSES OF LUNG TRIALS**
- Economic analyses - active and planned Dr. N. Leighl
- Database analyses Dr. F. Shepherd